GenoMELPREDICT:基于家族史与胰腺癌史预测CDKN2A突变携带概率
研究基于国际GenoMEL联盟2116例家族性黑色素瘤病例,验证MELPREDICT模型并构建GenoMELPREDICT。MELPREDICT表现良好(AUC 0.752,95%CI 0.730-0.775),GenoMELPREDICT相似(AUC 0.748,95%CI 0.726-0.771)。加入胰腺癌史可改善判别(AUC 0.772,95%CI 0.750-0.793,NRI 0.40,P<.0001),表型风险因素未提升性能。
要点
- MELPREDICT模型在全球家族性黑色素瘤病例中验证良好。
- 加入胰腺癌史可小幅提升CDKN2A突变预测判别力。
- GenoMELPREDICT可辅助筛选需遗传检测或癌症风险咨询的患者。
核心结论
- MELPREDICT模型在全球家族性黑色素瘤数据集中表现良好,加入胰腺癌史可改善预测性能。
- GenoMELPREDICT是预测家族性黑色素瘤患者CDKN2A突变状态的简便工具。
研究设计与样本
- 国际GenoMEL联盟纳入2116例家族性黑色素瘤病例。
- 在数据中复现MELPREDICT模型(GenoMELPREDICT),评估加入表型风险因素和胰腺癌史后的性能改进。
- 性能指标包括曲线下面积(AUC)及95%置信区间(CI)和净重分类指数(NRI)。
主要发现
- MELPREDICT表现良好,AUC 0.752(95%CI 0.730-0.775)。
- GenoMELPREDICT性能相似,AUC 0.748(95%CI 0.726-0.771)。
- 加入报告的胰腺癌史后,GenoMELPREDICT判别改善(P<.0001),AUC 0.772(95%CI 0.750-0.793),NRI 0.40。
- 纳入表型风险因素未改善性能。
关键数值与推荐
- CDKN2A高外显率胚系突变在一般人群罕见,但占黑色素瘤易感家族中报告黑色素瘤病例的5%-40%。
临床怎么用
- GenoMELPREDICT可用于预测家族性黑色素瘤患者的CDKN2A突变状态。
- 该工具可辅助指导患者接受遗传检测或癌症风险咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although rare in the general population, highly penetrant germline mutations in CDKN2A are responsible for 5%-40% of melanoma cases reported in melanoma-prone families. We sought to determine whether MELPREDICT was generalizable to a global series of families with melanoma and whether performance improvements can be achieved. METHODS: In total, 2116 familial melanoma cases were ascertained by the international GenoMEL Consortium. We recapitulated the MELPREDICT model within our data (GenoMELPREDICT) to assess performance improvements by adding phenotypic risk factors and history of pancreatic cancer. We report areas under the curve (AUC) with 95% confidence intervals (CIs) along with net reclassification indices (NRIs) as performance metrics. RESULTS: MELPREDICT performed well (AUC 0.752, 95% CI 0.730-0.775), and GenoMELPREDICT performance was similar (AUC 0.748, 95% CI 0.726-0.771). Adding a reported history of pancreatic cancer yielded discriminatory improvement (P < .0001) in GenoMELPREDICT (AUC 0.772, 95% CI 0.750-0.793, NRI 0.40). Including phenotypic risk factors did not improve performance. CONCLUSION: The MELPREDICT model functioned well in a global data set of familial melanoma cases. Adding pancreatic cancer history improved model prediction. GenoMELPREDICT is a simple tool for predicting CDKN2A mutational status among melanoma patients from melanoma-prone families and can aid in directing these patients to receive genetic testing or cancer risk counseling.
引用
- Taylor NJ, Mitra N, Qian L, et al. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. J Am Acad Dermatol. 2019. PMID: 30731170. doi:10.1016/j.jaad.2019.01.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。